inter alia, diagnosis and therapy of human diseases asso­ciated with surfactant deficiency. Exemplary cell lines of the present invention designated as NCI-H441-4, NCI-H820, NCI-H322 and NCI-H1404 are deposited with the American Type Culture Collection (ATCC) of Rockville, Maryland under accession Nos. CRL 9400, CRL 9531, CRL 9532 and CRL 9533, respectively. The present invention also relates to a novel method for regulating the expression of a surfactant-asso­ciated protein by cells having the ability to express at least one surfactant-associated protein and/or mRNA encoding therefore by exposing the cells to a regulating agent, such as a glucocorticoid hormone, 8-Br-cAMP or a functional equivalent, to selectively induce or inhibit the expression of a surfactant-associated protein. The present invention is also directed to novel methods to screen for tumor cells of pulmonary epithelial origin which produce surfactant-associated proteins and purifying the proteins from lysates of the cells or the media. The present invention also relates to novel human proteins, Mr=40-46,000, Mr=27-33,000 and Mr=23,000 on SDS-PAGE, which are believed to be precursors of the SPL(Phe) human protein. The SPL(Phe) mRNA initially translates an Mr=40-42,000 preproprotein which is glycosylated at asparagine residues and sialylated resulting in an Mr=40-46,000 SPL(Phe) proprotein. The Mr=27-33,000 protein is a proteolytically cleaved fragment of the Mr=40-46,000 precursor, and the Mr=23,000 protein results from de-glycosylating and de-sialylating the Mr=27-33,000 protein."/> Human cell lines of epithelial lung adenocarcinoma origin, human proteins and methods
首页> 外国专利> Human cell lines of epithelial lung adenocarcinoma origin, human proteins and methods

Human cell lines of epithelial lung adenocarcinoma origin, human proteins and methods

机译:上皮性肺腺癌起源的人类细胞系,人类蛋白质和方法

摘要

The present invention relates to novel continuous human adenocarcinoma cell lines of epithe­lial lung tissue origin that produce fully processed or semi-processed surfactant-associated proteins, e.g., SAP-35 and SPL(Phe). The surfactant-associated proteins confer biological activity to pulmonary surfactant phospholipids and are useful for formu­lating pulmonary surfactant replacement for, inter alia, diagnosis and therapy of human diseases asso­ciated with surfactant deficiency. Exemplary cell lines of the present invention designated as NCI-H441-4, NCI-H820, NCI-H322 and NCI-H1404 are deposited with the American Type Culture Collection (ATCC) of Rockville, Maryland under accession Nos. CRL 9400, CRL 9531, CRL 9532 and CRL 9533, respectively. The present invention also relates to a novel method for regulating the expression of a surfactant-asso­ciated protein by cells having the ability to express at least one surfactant-associated protein and/or mRNA encoding therefore by exposing the cells to a regulating agent, such as a glucocorticoid hormone, 8-Br-cAMP or a functional equivalent, to selectively induce or inhibit the expression of a surfactant-associated protein. The present invention is also directed to novel methods to screen for tumor cells of pulmonary epithelial origin which produce surfactant-associated proteins and purifying the proteins from lysates of the cells or the media. The present invention also relates to novel human proteins, Mr=40-46,000, Mr=27-33,000 and Mr=23,000 on SDS-PAGE, which are believed to be precursors of the SPL(Phe) human protein. The SPL(Phe) mRNA initially translates an Mr=40-42,000 preproprotein which is glycosylated at asparagine residues and sialylated resulting in an Mr=40-46,000 SPL(Phe) proprotein. The Mr=27-33,000 protein is a proteolytically cleaved fragment of the Mr=40-46,000 precursor, and the Mr=23,000 protein results from de-glycosylating and de-sialylating the Mr=27-33,000 protein.
机译:本发明涉及上皮肺组织来源的新型连续人腺癌细胞系,其产生完全加工或半加工的表面活性剂相关蛋白,例如SAP-35和SPL(Phe)。与表面活性剂相关的蛋白质赋予肺表面活性剂磷脂生物活性,可用于配制肺表面活性剂替代品,尤其是用于与表面活性剂缺乏相关的人类疾病的诊断和治疗。命名为NCI-H441-4,NCI-H820,NCI-H322和NCI-H1404的本发明的示例性细胞系保藏在马里兰州罗克维尔的美国典型培养物保藏中心(ATCC),保藏号为CRL 9400,CRL 9531。 ,CRL 9532和CRL 9533。本发明还涉及一种新颖的方法,该方法通过使细胞暴露于调节剂(例如,细胞)来调节具有与表面活性剂相关的蛋白质和/或因此编码的mRNA的能力的细胞调节表面活性剂相关的蛋白质的表达。糖皮质激素,8-Br-cAMP或功能等同物,以选择性地诱导或抑制表面活性剂相关蛋白的表达。本发明<!-EPO ->还涉及筛选肺上皮来源的肿瘤细胞的新方法,所述肿瘤细胞产生表面活性剂相关蛋白并从细胞的裂解物中纯化蛋白。媒体。本发明还涉及新型人蛋白质,在SDS-PAGE上Mr = 40-46,000,Mr = 27-33,000和Mr = 23,000,被认为是SPL(Phe)人蛋白质的前体。 SPL(Phe)mRNA最初翻译一个Mr = 40-42,000前原蛋白,该蛋白在天冬酰胺残基处被糖基化并被唾液酸化,从而产生Mr = 40-46,000 SPL(Phe)前蛋白。 Mr = 27-33,000蛋白是Mr = 40-46,000前体的蛋白水解切割片段,Mr = 23,000蛋白是通过对Mr = 27-33,000蛋白进行去糖基化和去唾液酸化作用产生的。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号